Truist notes Genmab (GMAB) reported Phase 3 results from the EPCORE DLBCL-1 trial in transplant-ineligible second-line positive diffuse large B-cell lymphoma patients. The study missed its overall survival endpoint. However, this outcome does not change the firm’s view on the key frontline DLBCL study, and Truist remains optimistic for a positive read-out this year. The firm has a Buy rating on the shares with a price target of $48.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GMAB:
- Genmab Reports Positive Phase 3 Progression-Free Survival Data for Epcoritamab in Relapsed/Refractory DLBCL
- AbbVie announces results for epcoritamab from Phase 3 EPCORE DLBCL-1 trial
- Genmab AS trading resumes
- Genmab says OS in Phase 3 trial did not reach statistical significance
- Genmab AS trading halted, news pending